NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$64.18 -0.61 (-0.94 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$64.18
Today's Range$64.02 - $65.57
52-Week Range$41.67 - $71.99
Volume336,238 shs
Average Volume538,183 shs
Market Capitalization$3.28 billion
P/E Ratio-8.56
Dividend YieldN/A
Beta1.83

About Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical logoUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is developing various biologics product candidates, including Burosumab, a human monoclonal antibody that is in Phase III study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It is also developing a range of small-molecule product candidates, such as UX007, a substrate replacement therapy that completed Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome. In addition, the company is developing adeno-associated virus 8 (AAV8) gene therapy products comprising DTX301, an AAV8 for the treatment of OTC deficiency; DTX401, an AAV8 gene therapy program for the treatment of patients with GSDIa; and DTX201, a FVIII gene therapy program for the treatment of hemophilia A. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RARE
CUSIPN/A
Phone415-483-8800

Debt

Debt-to-Equity RatioN/A
Current Ratio10.10
Quick Ratio10.06

Price-To-Earnings

Trailing P/E Ratio-8.56
Forward P/E Ratio-11.65
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.61 million
Price / Sales1,223.85
Cash FlowN/A
Price / CashN/A
Book Value$8.68 per share
Price / Book7.39

Profitability

EPS (Most Recent Fiscal Year)($7.50)
Net Income$-302,130,000.00
Net MarginsN/A
Return on Equity-46.22%
Return on Assets-39.24%

Miscellaneous

Employees520
Outstanding Shares49,770,000

Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical (NASDAQ:RARE) issued its quarterly earnings results on Monday, May, 7th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.81. The biopharmaceutical company had revenue of $10.68 million for the quarter, compared to analyst estimates of $56.58 million. During the same period in the prior year, the company earned ($1.63) EPS. View Ultragenyx Pharmaceutical's Earnings History.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Ultragenyx Pharmaceutical.

What price target have analysts set for RARE?

20 analysts have issued 1 year target prices for Ultragenyx Pharmaceutical's shares. Their predictions range from $55.00 to $83.00. On average, they expect Ultragenyx Pharmaceutical's share price to reach $70.0556 in the next year. View Analyst Ratings for Ultragenyx Pharmaceutical.

What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?

Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. " (1/30/2018)
  • 2. JPMorgan Chase analysts commented, "RARE’s 3Q report this afternoon was relatively uneventful aside from a few small updates: 1) RARE now has biopsy data from 6 adult patients that are included in the FDA review of burosumab (KRN23); 2) 48 week Phase 3 data for burosumab in adults will be available by YE17; and 3) the DMTX acquisition could close as early as Nov 7 th . Additionally, the company plans on hosting an analyst day in NY on December 4 th during which they plan on sharing some additional details regarding their earlier stage pipeline." (11/5/2017)
  • 3. Cowen Inc analysts commented, "We continue to see Pacira’s Exparel franchise as one of the most durable in specialty pharma and we believe that, over time, Exparel will continue to gain acceptance in the ortho community." (6/29/2017)

Who are some of Ultragenyx Pharmaceutical's key competitors?

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the folowing people:
  • Dr. Emil D. Kakkis, Pres, CEO & Director (Age 58)
  • Ms. Shalini Sharp, Exec. VP & CFO (Age 43)
  • Ms. Karah Herdman Parschauer, Exec. VP and Gen. Counsel (Age 40)
  • Mr. John Richard Pinion II, Chief Quality Operations Officer and Exec. VP of Analytical Sciences & Research (Age 52)
  • Dr. Jayson Donald Alexander Dallas M.D., Chief Commercial Officer and Exec. VP (Age 50)

Has Ultragenyx Pharmaceutical been receiving favorable news coverage?

Media headlines about RARE stock have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ultragenyx Pharmaceutical earned a coverage optimism score of 0.09 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.42 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.51%), Federated Investors Inc. PA (2.41%), Northern Trust Corp (1.04%), Millennium Management LLC (0.60%), Schwab Charles Investment Management Inc. (0.45%) and Rock Springs Capital Management LP (0.35%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Shalini Sharp, Sunil Agarwal, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.

Which major investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including Legal & General Group Plc, Prudential Financial Inc., Point72 Asset Management L.P., Opaleye Management Inc., C WorldWide Group Holding A S, Smith Asset Management Group LP, Teacher Retirement System of Texas and California Public Employees Retirement System. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer and Theodore Alan Huizenga. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

Which major investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Federated Investors Inc. PA, UBS Group AG, Kornitzer Capital Management Inc. KS, Northern Trust Corp, Schwab Charles Investment Management Inc. and Highbridge Capital Management LLC. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $64.18.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $3.28 billion and generates $2.61 million in revenue each year. The biopharmaceutical company earns $-302,130,000.00 in net income (profit) each year or ($7.50) on an earnings per share basis. Ultragenyx Pharmaceutical employs 520 workers across the globe.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]


MarketBeat Community Rating for Ultragenyx Pharmaceutical (RARE)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  519 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  720
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
20 Wall Street analysts have issued ratings and price targets for Ultragenyx Pharmaceutical in the last 12 months. Their average twelve-month price target is $70.0556, suggesting that the stock has a possible upside of 9.15%. The high price target for RARE is $83.00 and the low price target for RARE is $55.00. There are currently 4 hold ratings and 16 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.802.792.682.41
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $70.0556$69.7647$69.5294$71.60
Price Target Upside: 9.15% upside27.21% upside44.31% upside51.31% upside

Ultragenyx Pharmaceutical (NASDAQ:RARE) Consensus Price Target History

Price Target History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2018BarclaysUpgradeEqual Weight ➝ Overweight$62.00 ➝ $74.00HighView Rating Details
5/10/2018Goldman SachsInitiated CoverageNeutral ➝ Neutral$63.00MediumView Rating Details
4/18/2018CowenReiterated RatingBuyMediumView Rating Details
4/18/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$74.00 ➝ $77.00HighView Rating Details
4/18/2018WedbushReiterated RatingOutperform ➝ Positive$64.00 ➝ $71.00HighView Rating Details
4/18/2018JMP SecuritiesBoost Price TargetOutperform$70.00 ➝ $74.00HighView Rating Details
4/18/2018SunTrust BanksUpgradeHold ➝ Buy$41.67 ➝ $55.00LowView Rating Details
4/17/2018Bank of AmericaBoost Price Target$61.00 ➝ $72.00LowView Rating Details
3/22/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$67.00MediumView Rating Details
2/23/2018Robert W. BairdReiterated RatingBuy$70.00MediumView Rating Details
2/21/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$57.00 ➝ $60.00HighView Rating Details
2/21/2018JPMorgan ChaseReiterated RatingMarket Outperform ➝ Overweight$68.00 ➝ $66.00HighView Rating Details
1/22/2018Evercore ISIUpgradeIn-Line ➝ OutperformHighView Rating Details
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$67.00LowView Rating Details
12/15/2017Raymond JamesReiterated RatingBuyLowView Rating Details
12/5/2017Canaccord GenuitySet Price TargetBuy$80.00MediumView Rating Details
12/4/2017Jefferies GroupUpgradeHold ➝ Buy$58.00 ➝ $72.00HighView Rating Details
8/23/2017Leerink SwannReiterated RatingOutperform$89.00 ➝ $83.00HighView Rating Details
8/8/2017HC WainwrightReiterated RatingNeutral ➝ Neutral$72.00 ➝ $75.00LowView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$72.00HighView Rating Details
11/30/2016CitigroupDowngradeNeutral ➝ SellN/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Ultragenyx Pharmaceutical (NASDAQ:RARE) Earnings History and Estimates Chart

Earnings by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) Earnings Estimates

2018 EPS Consensus Estimate: ($5.72)
2019 EPS Consensus Estimate: ($6.69)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($1.91)$0.91($0.52)
Q2 20185($2.24)($1.69)($2.02)
Q3 20185($2.24)($0.66)($1.23)
Q4 20185($2.23)($1.63)($1.95)
Q1 20191($1.64)($1.64)($1.64)
Q2 20191($1.66)($1.66)($1.66)
Q3 20191($1.68)($1.68)($1.68)
Q4 20191($1.71)($1.71)($1.71)

Ultragenyx Pharmaceutical (NASDAQ RARE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018($1.98)N/AView Earnings Details
5/7/2018Q1 2018($0.19)$0.62$56.58 million$10.68 millionViewN/AView Earnings Details
2/20/2018Q4 2017($2.00)($2.27)$0.75 million$2.41 millionViewListenView Earnings Details
11/2/2017Q3 2017($1.87)($1.87)$0.02 million$0.20 millionViewN/AView Earnings Details
7/27/2017Q2 2017($1.73)($1.72)$0.01 millionViewN/AView Earnings Details
5/4/2017Q1 2017($1.7060)($1.63)$0.05 millionViewListenView Earnings Details
2/16/2017Q4 2016($1.72)($1.75)$0.05 million$0.01 millionViewN/AView Earnings Details
11/7/2016Q3($1.53)($1.64)$7.60 million$0.11 millionViewListenView Earnings Details
8/8/2016Q2($1.44)($1.46)$0.02 millionViewN/AView Earnings Details
5/9/2016Q1($1.29)($1.35)ViewN/AView Earnings Details
2/25/2016Q4($1.14)($1.42)ViewListenView Earnings Details
11/9/2015Q3($0.87)($1.03)ViewN/AView Earnings Details
8/13/2015Q215($0.63)($0.83)ViewListenView Earnings Details
5/11/2015Q1 15($0.54)($0.63)ViewListenView Earnings Details
3/25/2015Q414($0.53)($0.52)ViewListenView Earnings Details
11/10/2014Q314($0.46)($0.50)ViewN/AView Earnings Details
8/11/2014Q214($0.42)($0.45)ViewN/AView Earnings Details
5/12/2014Q114($0.37)($0.85)ViewN/AView Earnings Details
3/24/2014($0.38)($4.98)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ultragenyx Pharmaceutical (NASDAQ:RARE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ultragenyx Pharmaceutical (NASDAQ RARE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.40%
Institutional Ownership Percentage: 95.47%
Insider Trading History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical (NASDAQ RARE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2018Karah Herdman ParschauerEVPSell1,465$60.00$87,900.00View SEC Filing  
8/28/2017Emil D KakkisCEOBuy7,500$52.52$393,900.00430,569View SEC Filing  
5/26/2017Theodore Alan HuizengaVPSell480$57.46$27,580.809,366View SEC Filing  
3/9/2017Theodore Alan HuizengaInsiderSell2,500$86.34$215,850.00View SEC Filing  
3/2/2017Shalini SharpCFOSell12,000$90.10$1,081,200.0067,887View SEC Filing  
2/27/2017Shalini SharpCFOSell12,000$80.14$961,680.0063,887View SEC Filing  
12/5/2016William AliskiDirectorSell6,000$78.19$469,140.0065,985View SEC Filing  
11/9/2016Shalini SharpCFOSell24,000$71.20$1,708,800.0069,387View SEC Filing  
10/19/2016Shalini SharpCFOSell12,000$61.40$736,800.0057,387View SEC Filing  
10/14/2016Emil D KakkisCEOSell20,000$63.02$1,260,400.00480,632View SEC Filing  
8/15/2016Emil D KakkisCEOSell20,000$67.61$1,352,200.00493,244View SEC Filing  
7/21/2016Sunil AgarwalInsiderSell649$52.68$34,189.32View SEC Filing  
7/15/2016Emil D KakkisCEOSell20,000$50.85$1,017,000.00513,597View SEC Filing  
6/20/2016Sunil AgarwalInsiderSell650$54.16$35,204.00View SEC Filing  
5/24/2016Sunil AgarwalInsiderSell650$66.00$42,900.007,111View SEC Filing  
5/16/2016Emil D KakkisCEOSell20,000$59.95$1,199,000.00526,704View SEC Filing  
4/20/2016Sunil AgarwalInsiderSell649$70.53$45,773.979,216View SEC Filing  
4/15/2016Emil D KakkisCEOSell20,000$70.33$1,406,600.00552,729View SEC Filing  
3/22/2016Sunil AgarwalInsiderSell650$61.45$39,942.509,608View SEC Filing  
2/22/2016Sunil AgarwalInsiderSell658$63.48$41,769.84View SEC Filing  
1/20/2016Sunil AgarwalinsiderSell585$72.83$42,605.5512,190View SEC Filing  
12/31/2015Emil D. KakkisCEOSell20,000$114.52$2,290,400.00575,640View SEC Filing  
12/22/2015Sunil AgarwalInsiderSell498$114.81$57,175.3813,231View SEC Filing  
12/18/2015Theodore Alan HuizengainsiderSell1,500$110.55$165,825.002,500View SEC Filing  
8/20/2015Sunil AgarwalinsiderSell17,020$111.18$1,892,283.6016,900View SEC Filing  
8/12/2015Thomas Richard KassbergSVPSell3,334$109.70$365,739.80View SEC Filing  
7/20/2015Shalini SharpCFOSell3,854$131.95$508,535.30View SEC Filing  
7/8/2015Thomas Richard KassbergSVPSell3,334$102.12$340,468.08View SEC Filing  
6/18/2015Shalini SharpCFOSell4,000$96.08$384,320.00View SEC Filing  
6/17/2015Theodore Alan HuizengaInsiderSell1,500$94.80$142,200.00View SEC Filing  
6/10/2015Thomas Richard KassbergSVPSell3,334$88.19$294,025.46View SEC Filing  
4/20/2015Shalini SharpCFOSell4,000$62.23$248,920.00View SEC Filing  
4/8/2015Thomas Richard KassbergSVPSell3,333$58.02$193,380.66View SEC Filing  
1/20/2015Shalini SharpCFOSell4,000$51.24$204,960.00View SEC Filing  
12/18/2014Shalini SharpCFOSell4,000$44.82$179,280.00View SEC Filing  
12/10/2014Thomas Richard KassbergSVPSell3,333$40.22$134,053.26View SEC Filing  
12/4/2014William AliskiDirectorSell6,000$42.16$252,960.00View SEC Filing  
11/20/2014Shalini SharpCFOSell4,000$44.07$176,280.00View SEC Filing  
11/12/2014Thomas Richard KassbergSVPSell3,333$41.85$139,486.05View SEC Filing  
10/8/2014Thomas Richard KassbergSVPSell3,333$53.26$177,515.58View SEC Filing  
9/18/2014Shalini SharpCFOSell4,000$56.00$224,000.00View SEC Filing  
9/10/2014Thomas Richard KassbergSVPSell3,333$54.82$182,715.06View SEC Filing  
9/3/2014Thomas Richard KassbergSVPSell20,000$53.91$1,078,200.00View SEC Filing  
8/18/2014Shalini SharpCFOSell4,000$53.97$215,880.00View SEC Filing  
7/14/2014Group Holdings (Sbs) Advis TpgInsiderSell488,820$37.60$18,379,632.00View SEC Filing  
1/31/2014Fmr LlcInsiderBuy175,000$21.00$3,675,000.00View SEC Filing  
1/30/2014Shalini SharpCFOBuy4,500$21.00$94,500.00View SEC Filing  
1/30/2014Thomas Richard KassbergSVPBuy1,500$21.00$31,500.00View SEC Filing  
1/30/2014William AliskiDirectorBuy5,000$21.00$105,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ultragenyx Pharmaceutical (NASDAQ RARE) News Headlines

Source:
DateHeadline
Ultragenyx Pharmaceutical (RARE) Upgraded at BidaskClubUltragenyx Pharmaceutical (RARE) Upgraded at BidaskClub
www.americanbankingnews.com - May 19 at 11:03 AM
Ultragenyx and Kyowa Hakko Kirins Crysvita beats conventional therapy in late-stage XLH studyUltragenyx and Kyowa Hakko Kirin's Crysvita beats conventional therapy in late-stage XLH study
seekingalpha.com - May 18 at 8:42 AM
Ultragenyx Pharma (RARE), Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of ...Ultragenyx Pharma (RARE), Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of ...
www.streetinsider.com - May 18 at 8:42 AM
BRIEF-Ultragenyx, Kyowa Kirin Say Crysvita Met Main Goal Of Phase 3 StudyBRIEF-Ultragenyx, Kyowa Kirin Say Crysvita Met Main Goal Of Phase 3 Study
www.reuters.com - May 18 at 8:42 AM
$4.50 Million in Sales Expected for Ultragenyx Pharmaceutical (RARE) This Quarter$4.50 Million in Sales Expected for Ultragenyx Pharmaceutical (RARE) This Quarter
www.americanbankingnews.com - May 18 at 2:20 AM
Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results ...Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results ...
globenewswire.com - May 17 at 6:38 PM
Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)
finance.yahoo.com - May 17 at 6:38 PM
Zacks: Brokerages Anticipate Ultragenyx Pharmaceutical (RARE) to Announce -$2.14 EPSZacks: Brokerages Anticipate Ultragenyx Pharmaceutical (RARE) to Announce -$2.14 EPS
www.americanbankingnews.com - May 16 at 7:16 PM
Ultragenyx Pharmaceutical (RARE) Raised to Overweight at BarclaysUltragenyx Pharmaceutical (RARE) Raised to Overweight at Barclays
www.americanbankingnews.com - May 11 at 6:55 PM
Q2 2018 Earnings Estimate for Ultragenyx Pharmaceutical Issued By Jefferies Group (RARE)Q2 2018 Earnings Estimate for Ultragenyx Pharmaceutical Issued By Jefferies Group (RARE)
www.americanbankingnews.com - May 11 at 8:35 AM
Ultragenyx Pharmaceutical (RARE) EVP Karah Herdman Parschauer Sells 1,465 SharesUltragenyx Pharmaceutical (RARE) EVP Karah Herdman Parschauer Sells 1,465 Shares
www.americanbankingnews.com - May 10 at 8:21 PM
Ultragenyx Pharmaceutical (RARE) Now Covered by Analysts at Goldman SachsUltragenyx Pharmaceutical (RARE) Now Covered by Analysts at Goldman Sachs
www.americanbankingnews.com - May 10 at 7:51 PM
Piper Jaffray Comments on Ultragenyx Pharmaceuticals Q2 2018 Earnings (RARE)Piper Jaffray Comments on Ultragenyx Pharmaceutical's Q2 2018 Earnings (RARE)
www.americanbankingnews.com - May 10 at 6:44 AM
Wedbush Research Analysts Cut Earnings Estimates for Ultragenyx Pharmaceutical (RARE)Wedbush Research Analysts Cut Earnings Estimates for Ultragenyx Pharmaceutical (RARE)
www.americanbankingnews.com - May 10 at 6:44 AM
Ultragenyx Pharmaceutical Expected to Earn Q2 2018 Earnings of ($2.24) Per Share (RARE)Ultragenyx Pharmaceutical Expected to Earn Q2 2018 Earnings of ($2.24) Per Share (RARE)
www.americanbankingnews.com - May 10 at 6:44 AM
Ultragenyx Pharmaceuticals: Many Upcoming CatalystsUltragenyx Pharmaceuticals: Many Upcoming Catalysts
seekingalpha.com - May 9 at 8:20 AM
Its Raining FDA Approvals, MSON Muscling Up, RDHL To Report Data In Aug.It's Raining FDA Approvals, MSON Muscling Up, RDHL To Report Data In Aug.
www.nasdaq.com - May 8 at 8:17 AM
Form 10-Q Ultragenyx Pharmaceutica For: Mar 31Form 10-Q Ultragenyx Pharmaceutica For: Mar 31
www.streetinsider.com - May 8 at 8:17 AM
Ultragenyx Pharmaceuticals (RARE) CEO Emil Kakkis on Q1 2018 Results - Earnings Call TranscriptUltragenyx Pharmaceutical's (RARE) CEO Emil Kakkis on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 8:17 AM
Edited Transcript of RARE earnings conference call or presentation 7-May-18 9:00pm GMTEdited Transcript of RARE earnings conference call or presentation 7-May-18 9:00pm GMT
finance.yahoo.com - May 8 at 8:17 AM
Ultragenyx Pharmaceutical (RARE) Announces Quarterly  Earnings ResultsUltragenyx Pharmaceutical (RARE) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 7 at 6:44 PM
Ultragenyx Reports First Quarter 2018 Financial Results and Corporate UpdateUltragenyx Reports First Quarter 2018 Financial Results and Corporate Update
finance.yahoo.com - May 7 at 5:37 PM
Ultragenyx: 1Q Earnings SnapshotUltragenyx: 1Q Earnings Snapshot
finance.yahoo.com - May 7 at 5:37 PM
Ultragenyx Pharmaceutical (RARE) Upgraded to Buy at BidaskClubUltragenyx Pharmaceutical (RARE) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - May 7 at 11:58 AM
Ultragenyx Pharmaceutical (RARE) Given Consensus Rating of "Buy" by AnalystsUltragenyx Pharmaceutical (RARE) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 7 at 9:09 AM
The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And MoreThe Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More
feeds.benzinga.com - May 6 at 7:21 PM
How The Parts Add Up: JKK Targets $211How The Parts Add Up: JKK Targets $211
www.nasdaq.com - May 1 at 5:17 PM
Ultragenyx Pharma (RARE) & Kyowa Kirin Announce Launch of Crysvita (burosumab-twza) in USUltragenyx Pharma (RARE) & Kyowa Kirin Announce Launch of Crysvita (burosumab-twza) in US
www.streetinsider.com - May 1 at 5:17 PM
BRIEF-Ultragenyx And Kyowa Kirin Announce Crysvita® (Burosumab-Twza) Now Launched In The USBRIEF-Ultragenyx And Kyowa Kirin Announce Crysvita® (Burosumab-Twza) Now Launched In The US
www.reuters.com - May 1 at 5:17 PM
Ultragenyx to Host Conference Call for First Quarter 2018 Financial Results and Corporate UpdateUltragenyx to Host Conference Call for First Quarter 2018 Financial Results and Corporate Update
finance.yahoo.com - May 1 at 5:17 PM
Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in ...Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in ...
globenewswire.com - May 1 at 8:26 AM
Ultragenyx Pharmaceutical (RARE) Downgraded by BidaskClubUltragenyx Pharmaceutical (RARE) Downgraded by BidaskClub
www.americanbankingnews.com - May 1 at 8:12 AM
Ultragenyx Pharmaceutical (RARE) Expected to Announce Quarterly Sales of $53.42 MillionUltragenyx Pharmaceutical (RARE) Expected to Announce Quarterly Sales of $53.42 Million
www.americanbankingnews.com - May 1 at 4:10 AM
Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in the U.S. for the Treatment of X–linked Hypophosphatemia (XLH) in Children and AdultsUltragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in the U.S. for the Treatment of X–linked Hypophosphatemia (XLH) in Children and Adults
finance.yahoo.com - April 30 at 5:13 PM
-$0.60 Earnings Per Share Expected for Ultragenyx Pharmaceutical (RARE) This Quarter-$0.60 Earnings Per Share Expected for Ultragenyx Pharmaceutical (RARE) This Quarter
www.americanbankingnews.com - April 29 at 5:16 AM
BRIEF-Ultragenyx Announces Filing And FDA Clearance Of An Investigational New Drug Application For DTX401BRIEF-Ultragenyx Announces Filing And FDA Clearance Of An Investigational New Drug Application For DTX401
www.reuters.com - April 25 at 5:28 PM
Investor Expectations to Drive Momentum within MicroStrategy, Marcus & Millichap, Gentex, Ultragenyx Pharmaceutical, Dave & Busters Entertainment, and Glatfelter — Discovering Underlying Factors of InfluenceInvestor Expectations to Drive Momentum within MicroStrategy, Marcus & Millichap, Gentex, Ultragenyx Pharmaceutical, Dave & Buster's Entertainment, and Glatfelter — Discovering Underlying Factors of Influence
finance.yahoo.com - April 25 at 8:20 AM
Ultragenyx Pharmaceutical (RARE) Set to Announce Earnings on WednesdayUltragenyx Pharmaceutical (RARE) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - April 25 at 4:28 AM
Ultragenyx Announces Filing and FDA Clearance of an Investigational New Drug ...Ultragenyx Announces Filing and FDA Clearance of an Investigational New Drug ...
globenewswire.com - April 23 at 5:13 PM
FDA on board with start of clinical development of UltraGenyxs DTX401 for glycogen storage disorderFDA on board with start of clinical development of UltraGenyx's DTX401 for glycogen storage disorder
seekingalpha.com - April 23 at 5:13 PM
Ultragenyx Announces Filing and FDA Clearance of an Investigational New Drug Application for DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type IaUltragenyx Announces Filing and FDA Clearance of an Investigational New Drug Application for DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia
finance.yahoo.com - April 23 at 5:13 PM
2 Derisked Small Biotechs To Buy Now2 'Derisked' Small Biotechs To Buy Now
seekingalpha.com - April 20 at 5:21 PM
FY2018 EPS Estimates for Ultragenyx Pharmaceutical Raised by SunTrust Banks (RARE)FY2018 EPS Estimates for Ultragenyx Pharmaceutical Raised by SunTrust Banks (RARE)
www.americanbankingnews.com - April 20 at 8:26 AM
Q1 2018 EPS Estimates for Ultragenyx Pharmaceutical (RARE) Increased by Leerink SwannQ1 2018 EPS Estimates for Ultragenyx Pharmaceutical (RARE) Increased by Leerink Swann
www.americanbankingnews.com - April 20 at 7:08 AM
Wedbush Analysts Boost Earnings Estimates for Ultragenyx Pharmaceutical (RARE)Wedbush Analysts Boost Earnings Estimates for Ultragenyx Pharmaceutical (RARE)
www.americanbankingnews.com - April 20 at 7:08 AM
Ultragenyx Pharmaceuticals (RARE) Buy Rating Reiterated at CowenUltragenyx Pharmaceutical's (RARE) Buy Rating Reiterated at Cowen
www.americanbankingnews.com - April 18 at 9:10 PM
Ultragenyx Pharmaceutical Wins Approval For Drug Treating Rare Form Of RicketsUltragenyx Pharmaceutical Wins Approval For Drug Treating Rare Form Of Rickets
finance.yahoo.com - April 18 at 5:44 PM
Ultragenyx Pharmaceutical (RARE) Rating Reiterated by WedbushUltragenyx Pharmaceutical (RARE) Rating Reiterated by Wedbush
www.americanbankingnews.com - April 18 at 9:51 AM
Ultragenyx Pharmaceutical (RARE) Given New $74.00 Price Target at JMP SecuritiesUltragenyx Pharmaceutical (RARE) Given New $74.00 Price Target at JMP Securities
www.americanbankingnews.com - April 18 at 9:50 AM
Ultragenyx Pharmaceutical (RARE) Price Target Raised to $77.00 at Stifel NicolausUltragenyx Pharmaceutical (RARE) Price Target Raised to $77.00 at Stifel Nicolaus
www.americanbankingnews.com - April 18 at 9:47 AM

SEC Filings

Ultragenyx Pharmaceutical (NASDAQ:RARE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ultragenyx Pharmaceutical (NASDAQ:RARE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ultragenyx Pharmaceutical (NASDAQ RARE) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.